Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Inclusion Criteria

• •Histological or cytological documented NSCLC, including squamous cell carcinoma, adenocarcinoma, large cell carcinoma including large cell neuroendocrine carcinoma adenosquamous and sarcomatoid carcinomas.
• •Patients with Pancoast tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field. Pancoast tumor patients will be so-noted in the registry.
• •Patients must be ≥ 18 years of age.
• •Patients with Zubrod (ECOG) performance status ≤ 2.
• •Adequate hematologic function defined as: ANC ≥ 1000/mm3, platelets ≥ 75,000/mm3, and hemoglobin ≥ 8 g/dL (prior to transfusions); adequate hepatic function defined as: total bilirubin ≤ 3.0 mg/dl, and adequate renal function defined as a serum creatinine level ≤ 2.0 mg/dl.
• •Patients with weight loss ≤ 20% over the past 3 months.
• •Patients with a pleural effusion that is proven cytologically negative or is too small to tap.
• •Women of childbearing potential must agree to practice effective contraception throughout the study and for four weeks after completion of treatment.
• •Pretreatment evaluations required for eligibility include:
• •* A medical history, physical examination, and assessment of Zubrod performance status within 4 weeks prior to study entry.
• •* CBC with differential and platelet count, and laboratory profile must be completed within 4 weeks prior to study entry.
• •* CT scan of the chest or whole body PET (preferred), and a CT scan or MRI (preferred) of the brain within 4 weeks prior to study entry.
• •* For women of childbearing potential, a serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) must be performed within a week prior to the start of protocol treatment.
• •* Medical Oncology and Radiation Oncology consultation and approval.
• •Patients must sign a study-specific consent form prior to study entry.